Showing results (121-130 of 312) with videos related to

Sort By:
Pageof 32
Journal of Geriatric Oncology|November 25, 2020
Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic reviewAnupam Batra, Michele Marchioni, Ardeshir Z Hashmi, et al.
Urologic Oncology|May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist, Malcolm J Moore, Kim N Chi, et al.
Cureus|March 7, 2024
Personalized Treatment of Recurrent, Metastatic Head and Neck Cancer Guided by Patient-Derived Xenograft ModelsMorgan D Black, John Yoo, Kevin Fung, et al.
Cureus|May 30, 2023
Stereotactic or Conventional Radiation for Early-Stage Non-small Cell Lung Cancer: A Systematic Review and Meta-AnalysisAdam Mutsaers, Tina Wanting Zhang, Alexander Louie, et al.
American Journal of Clinical Oncology|March 27, 2019
Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysisJacques Raphael, Mark Vincent, Gabriel Boldt, et al.
Cureus|December 2, 2015
Abscopal Effects: Case Report and Emerging OpportunitiesMichael Lock, Ahmad Muinuddin, Walter I Kocha, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 10, 2018
Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxelDaniel W Yokom, John Stewart, Nimira S Alimohamed, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 25, 2016
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abirateroneFred Saad, Eric Winquist, Stacey Hubay, et al.
Medicine|August 20, 2015
A Population-Based Study of 30-day Incidence of Ischemic Stroke Following Surgical Neck DissectionS Danielle MacNeil, Kuan Liu, Amit X Garg, et al.
Advances in Radiation Oncology|November 5, 2019
A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity AnalysisLaura Callan, Glenn Bauman, Jeff Chen, et al.
Pageof 32